AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Eli Lilly's Mounjaro Reduces Cancer Risk: Analysts Expect Significant Upside for Stock
ByAinvest
Friday, Aug 22, 2025 12:02 pm ET1min read
Eli Lilly's Mounjaro has shown potential in reducing overall cancer risk in recent research. Analyst price targets suggest a significant upside for Eli Lilly's stock, with an average 1-year target of $892.33 and a potential 24.84% increase from its current price. Current brokerage recommendations rate Eli Lilly as "Outperform" with a consensus rating of 2.0.
Eli Lilly's (LLY) Mounjaro, a GLP-1 receptor agonist, has shown promise in reducing overall cancer risk according to recent research. The study, published on Jama Oncology, analyzed electronic health records of over 80,000 obese individuals, revealing a significant reduction in cancer risk among users of GLP-1 medications compared to non-users [2]. However, the study also noted a slight uptick in kidney cancer risk.Analysts are optimistic about Eli Lilly's stock prospects. The average one-year price target for Eli Lilly and Co (LLY) is $892.33, suggesting a potential 24.84% increase from its current price of $714.78 [1]. Brokerage recommendations also favor Eli Lilly, with a consensus rating of 2.0, indicating an "Outperform" status [1].
Eli Lilly's Mounjaro is not the only GLP-1 drug linked to lower cancer risk. Novo Nordisk's Ozempic, another GLP-1 receptor agonist, has also shown similar findings in the study [2]. The study led by Hao Dai, a health data scientist at Indiana University, suggests that the incidence rate for 14 cancer types stood at 13.6 among GLP-1 users compared to 16.4 among non-users [2].
While the findings are promising, the study calls for a longer-term follow-up to evaluate the clinical implications and reasons behind the findings [2]. The retrospective nature of the study and the fact that no GLP-1 drugs are indicated for cancer underscore the need for further research.
References:
[1] https://www.gurufocus.com/news/3075549/eli-lillys-lly-mounjaro-shows-potential-in-reducing-cancer-risk
[2] https://seekingalpha.com/news/4488383-glp-1-drugs-are-linked-lower-cancer-risk
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet